eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

without publication fees

Otwarty dostęp

without publication fees
1/2024
vol. 40
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
Artykuł przeglądowy

Lekanemab w leczeniu choroby Alzheimera we wczesnym stadium – przegląd literatury

Wiktor Szymajda
1
,
Łukasz Salamaga
1
,
Weronika Skoczek
1
,
Bartosz Zaleski
1
,
Mikołaj Araszewski
1
,
Ada Kaczmarek
1, 2
,
Grzegorz Kolasa
2

  1. Faculty of Medicine, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
Farmakoterapia w Psychiatrii i Neurologii 2024, 40 (1), 31–42
DOI: https://doi.org/10.5114/fpn.2024.140847
Data publikacji online: 2024/08/01
Plik artykułu:
- 04_IPiN_FARM_2024-1C_akc.pdf  [0.17 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Alzforum [Internet]. Leqembi. Available from: https://www.alzforum.org/therapeutics/leqembi (last accessed on 12.05.2023).
2. Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021; 17: 327–406
3. Bello AM, Olalekan SK, Azizah U, Wael M, Haziq K, Husna IN et al. Alzheimer’s Disease: An Update and Insights Into Pathophysiology. Front Aging Neurosci. 2022; 14: 742408.
4. Cummings J, Salloway S. Aducanumab: Appropriate use recommendations. Alzheimers Dement. 2022; 18: 531–533.
5. Food and Drug Administration. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval [Internet]. Available from: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval (last accessed on 23.06.2023). (a)
6. Food and Drug Administration. FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment [Internet]. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimersdisease-treatment (last accessed on 08.08.2023). (b)
7. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11: S33–39.
8. Hoy SM. Lecanemab: First Approval. Drugs. 2023; 83: 359–365.
9. Husain MA, Laurent B, Plourde M. APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics. Front Neurosci 2021; 15: 630502.
10. InformedHealth.org [Internet]. Non-drug interventions for Alzheimer’s disease. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279355/ (last accessed on 04.06.2023).
11. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015; 11(1): 1–15.e1–4.
12. McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M et al. Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther 2022; 14: 191.
13. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging – Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7: 263–269.
14. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11: S13–21.
15. National Institute of Aging [Internet]. Available from: https://www.nia.nih.gov/health/how-alzheimers-diseasetreated (last accessed on 25.06.2023).
16. Młynarczyk R, Bochon B, Piontek A, Kunert Ł, Sobiś J, Gorczyca PW. Choroba Alzheimera – nowe strategie leczenia. Psychiatr. 2016; 13: 210–214.
17. Marasco RA. Current and evolving treatment strategies for the Alzheimer disease continuum. Am J Manag Care 2020; 26: S167-S176.
18. Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G et al. Lecanemab, Aducanumab, and Gantenerumab – Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease. Neurotherapeutics. 2023; 20: 195–206.
19. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK et al. A randomized, double-blind, phase 2b proofof- concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021; 13: 80. Erratum in: Alzheimers Res Ther. 2022.
20. Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling. Neurol Ther. 2022; 11: 863–880.
21. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med 2023; 388: 9–21.
22. Vaz M, Silva V, Monteiro C, Silvestre S. Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities. Clin Interv Aging. 2022; 17: 797–810.
23. Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry 2016; 87: 993–999.
24. Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: An update. J. Cent. Nerv. Syst. Dis. 2020; 12: 1179573520907397.

Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Czasopisma Aktualności Książki eBooki Konferencje i webinary
Serwisy
KONGRES TOP MEDICAL TRENDS Koronawirus Zalecenia i rekomendacje Lekarz POZ Kurier Medyczny Dermatologia Diabetologia e-Praktyka Leczenia Ran Ginekologia Neurologia Onkologia Pulmonologia Reumatologia Menedżer Zdrowia Warto wiedzieć
e-Akademia
e-Akademia Raka Płuca e-Akademia MAFLD e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń e-Akademia Chorób Cywilizacyjnych Akademia Zapalenia typu 2 Akademia AZScience
© 2024 Termedia Sp. z o.o.
Developed by Bentus.